+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Thrombocytopenic Purpura Drug"

Immune Thrombocytopenic Purpura - Pipeline Insight, 2024 - Product Thumbnail Image

Immune Thrombocytopenic Purpura - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Acquired Thrombotic Thrombocytopenic Purpura - Pipeline Insight, 2024 - Product Thumbnail Image

Acquired Thrombotic Thrombocytopenic Purpura - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Thrombotic thrombocytopenic purpura - Pipeline Insight, 2024 - Product Thumbnail Image

Thrombotic thrombocytopenic purpura - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2024 - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
US Thrombotic Thrombocytopenic Purpura (TTP) - Epidemiology Forecast to 2030 - Product Thumbnail Image

US Thrombotic Thrombocytopenic Purpura (TTP) - Epidemiology Forecast to 2030

  • Drug Pipelines
  • October 2021
  • 50 Pages
  • United States
From
From
From
From
Immune Thrombocytopenic Purpura - Epidemiology Forecast - 2032 - Product Thumbnail Image

Immune Thrombocytopenic Purpura - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
From
Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020 - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 180 Pages
  • Global
From
  • 20 Results (Page 1 of 1)
Loading Indicator

Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by a low platelet count. It is treated with a variety of hematological drugs, including corticosteroids, immunosuppressants, and anticoagulants. Corticosteroids are used to reduce inflammation and suppress the immune system, while immunosuppressants are used to reduce the body's production of antibodies. Anticoagulants are used to prevent the formation of blood clots. These drugs are used in combination to reduce the risk of bleeding and improve platelet counts. The market for TTP drugs is highly competitive, with a number of companies offering a range of products. Some of the major players in the market include Pfizer, Novartis, Merck, and Bristol-Myers Squibb. Other companies include AbbVie, AstraZeneca, and Sanofi. These companies offer a range of products, including generic and branded drugs, to meet the needs of patients with TTP. Show Less Read more